JGJingjing Gan

Jingjing Gan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jingjing Gan has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Lingyun Sun

    Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

    2 shared publications
  • Yuanjin Zhao

    Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, China

    2 shared publications
  • Chang Xu

    Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210008, China

    1 shared publication
  • Chenhui Bai

    Department of Mechanical Engineering National University of Singapore Singapore Singapore

    1 shared publication
  • Danqing Huang

    Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Clinical Medical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China

    1 shared publication
  • Danqing Huang

    Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School

    1 shared publication

Latest Publications

  • Open Access

    Freeze‐Derived Microporous Biomaterials for Tissue Engineering Applications

    by Shuangshuang Miao, Xingkui Guo, Chenhui Bai, Wei Zhou, Yiwen Wu, Wanchuan Ding, Jingjing Gan

    Tissue engineering holds immense promise to revolutionize regenerative medicine by enabling the fabrication of functional, patient‐specific tissues and organs for clinical translation, yet it continues to face persistent challenges in designing scaffolds that simultaneously recapitulate native tissue architecture, support cell viability, and enable efficient mass transport. Traditional fabrication has moved the field forward, yet routinely falls short of producing hierarchical, anisotropic, biomimetic structures under gentle conditions. Ice‐templating (or freeze‐casting), which is based on freeze‐induced microphase separation, reframes the problem as crystal‐growth engineering. This review summarizes current fabrication strategies and their underlying mechanism of ice‐templating technology from physical and chemical perspectives. We then highlight recent advances in ice‐templating for tissue engineering application fields such as 3D cell culture, wound healing, bone regeneration, nerve repair, and liver support, emphasizing the relationship between microstructure and biomedical functional performance. Finally, we discuss the key challenges in translating ice‐templated biomaterials from laboratory research to clinical practice and outline future directions to fully harness this versatile biomedical strategy.


  • Open Access

    Biomimetic flowing vessel-on-a-chip recruiting glycocalyx features for investigating dexmedetomidine function

    by Yi Zhang, Lina Lin, Jingjing Gan, Xiaoya Ding, Weijian Wang

  • Open Access

    Multi-component Microcapsules Derived Spatiotemporal Sonodynamic Reinforcing Therapy against Rheumatoid Arthritis

    by Danqing Huang, Min Nie, Rui Liu, Chang Xu, Jingjing Gan, Yuanjin Zhao, Lingyun Sun

    Microcarriers have demonstrated substantial potential in therapeutic delivery for rheumatoid arthritis (RA) treatment. Herein, we propose a novel spatiotemporal ultrasound-responsive microcapsule carrier to reinforce curcumin-based sonodynamic therapy in treating RA. Based on microfluidic technology, microcapsules with a hydrogel shell loaded with curcumin and a perfluorocarbon core enriched with oxygen (CUR/O 2 -MCs) can be obtained. Ascribed to the liquid-to-gas transition property of perfluorocarbon and the sonosensitivity of curcumin, ultrasound stimulation can realize controlled oxygen release followed by sonodynamic reactive oxygen species production. We have demonstrated that the ultrasound-activated CUR/O 2 -MCs can elevate reactive oxygen species amounts in overproliferating fibroblast-like synoviocytes, subsequently inducing fibroblast-like synoviocyte apoptosis. In addition, the released curcumin and oxygen can bring about macrophage repolarization, antiangiogenesis, and hypoxia alleviation, which are also important in blocking RA progression. Thus, in collagen-induced arthritis rats, our spatiotemporal sonodynamic microcapsules can attenuate symptoms and reduce joint damage. These results indicate that our ultrasound-responsive multifunctional microcapsule is an ideal candidate for sonodynamic therapy enhancement and RA treatment.


  • MCP-1 and IL-4 encapsulated hydrogel particles with macrophages enrichment and polarization capabilities for systemic lupus erythematosus treatment

    by Shengjie Zhu, Danqing Huang, Qichen Luan, Yang Li, Jingjing Gan, Yuanjin Zhao, Lingyun Sun

    Macrophages play a pivotal role in systemic lupus erythematosus (SLE) therapy. Efforts have been made to develop multifunctional drug delivery systems capable of directing macrophage polarization. Here, we present a novel hyaluronic acid methacrylate (HAMA) hydrogel microparticle encapsulating multiple cytokines for SLE remission though enhancing macrophage functions. The HAMA microparticles loaded with monocyte chemotactic protein-1 (MCP-1) and interleukin-4 (IL-4) were fabricated by using a microfluidic technology. The released MCP-1 facilitates the aggregation of inflammatory macrophages, after which IL-4 induces the macrophage phenotype shift from inflammatory M1 to immune-protective M2, thus restoring immune balance. We have demonstrated in MRL/lpr mice that the hydrogel microparticles could improve their efficacy of intraperitoneal drug delivery, modulate immune function, and attenuate the disease symptoms. These results suggest that our proposed microparticles delivery platform has potential clinical value for treating autoimmune diseases.